Six drugs in Table 1, namely oxyphencyclimine targeting CHRM3, phenethyl isothiocyanate targeting HSPA4, crizotinib targeting MST1R, pralsetinib targeting DDR1, trimebutine targeting CACNA1D, and tofacitinib targeting TYK2, have been used or studied in trials for the treatment of lung or GIT diseases [29]. The gene discussed is CHRM3; the disease is digestive system disorder.